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Purpose: To demonstrate the role of intravitreal bevacizumab in regression of iris neovascu-
larization, and intraocular pressure (IOP) control in neovascular glaucoma.
Methods: A retrospective random case series study was performed. Twenty eyes of 20 patients 
who presented with neovascular glaucoma were treated with intravitreal bevacizumab 2.5 mg in 
0.1 mL. Retinal photocoagulation was performed for all cases as soon as possible after intravitreal 
injection and subscleral trabeculectomy with mitomycin C 0.4 mg/mL for 3 minutes for cases 
having peripheral anterior synechiae. Cases were followed up for 12 months when regression 
of iris neovessels, IOP control, improvement in visual acuity, and success of filtering surgery 
were recorded.
Results: All cases showed complete regression of iris neovessels at 2 months after injection; 
recurrence of iris neovessels was observed in 4 cases (20%) at 4 months and in 14 cases (70%) 
at 8 months follow-up. The mean IOP dropped from 41.45 ± 5.89 mmHg preoperatively, 
to 19.3 ± 5.5 mmHg and 17.75 ± 3.74 mmHg at 6 months and 12 months postoperatively, 
respectively. The success rate of subscleral trabeculectomy with mitomycin C after intravitreal 
bevacizumab was 77.8%. Visual acuity was improved in 17 cases (85%) from preoperative 
0.12 ± 0.11 to 0.26 ± 0.2 postoperative.
Conclusion: Intravitreal bevacizumab has a role in regression of iris neovessels and IOP 
control in neovascular glaucoma cases and also in increasing the success rate of subscleral tra-
beculectomy with mitomycin C; however this role has a limited time and reinjection is needed 
to maintain this effect.
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Introduction
Ischemic retinopathies can cause new vessel growth on the iris surface and in the 
  anterior chamber angle, which can lead to neovascular glaucoma (NVG).   Dysregulation 
of vascular endothelial growth factor (VEGF), a mitogen specific for vascular 
  endothelial cells, has been implicated in several ocular diseases, including diabetic 
retinopathy and exudative age-related macular degeneration (AMD).1,2
NVG is an optic neuropathy caused by increased intraocular pressure (IOP), which 
results from secondary angle closure due to the growth of a neovascular membrane in 
the anterior chamber and trabecular meshwork.3,4
Most cases of NVG are caused by ischemic retinal diseases, such as diabetic retin-
opathy and central or branch retinal vein occlusions.4
The management of NVG includes lowering IOP (often surgically) and pan retinal 
photocoagulation (PRP), which reduces the production of vasoproliferative factors by Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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ischemic retina and can induce regression of anterior segment 
neovascularization.5
Bevacizumab is a neutralizing anti-VEGF recombinant 
humanized monoclonal antibody that is approved by the US 
Food and Drug Administration for the treatment of metastatic 
colorectal cancer and nonsmall cell lung cancer.6
Intravitreal bevacizumab (IVB) is used in an off-label 
fashion to treat VEGF-mediated ocular conditions such as 
choroidal revascularization secondary to AMD, diabetic 
macular edema, and central retinal vein occlusion-associated 
macular edema.7–9
Intravitreal bevacizumab was used in this study to evalu-
ate its role in NVG.
Patients and methods
A retrospective random case series study was performed 
to demonstrate the role of IVB in regression of iris neovas-
cularization, control of IOP, and its effect on the result of 
subscleral trabeculectomy with mitomycin C. The studied 
group consisted of 20 eyes of 20 patients presented with 
iris neovascularization and increased IOP as a complication 
of proliferative diabetic retinopathy or central retinal vein 
occlusion. Ocular examination included visual acuity (VA) 
assessment, slit lamp examination, gonioscopy, applanation 
tonometry, and indirect ophthalmoscopy.
All patients received IVB 2.5 mg in 0.1 mL after diagnosis 
of NVG. Intravitreal injection was performed as follows: eye 
speculum was applied, and conjunctival disinfection with 5% 
bovidine iodine, routine eye draping, and then intravitreal 
injection were done in the lower outer quadrant 3.5–4 mm 
posterior to the limbus.
Retinal photocoagulation was performed for all cases as 
soon as possible after intravitreal injection; laser was applied 
in 3–5 sessions with 250 µm spot sizes, at 200–450 mw power 
with the aim of completing 360° scatter PRP with a range of 
1000–1500 total shots.
All cases were followed up for 2 weeks for regression 
of iris neovascularization (NVI), then the 9 cases with 
  preinjection peripheral anterior synechiae (PAS) were treated 
by subscleral trabeculectomy (SST) as follows: fornix based 
conjunctival flap, one half thickness scleral flap 4 × 3 mm 
were performed, 2 sponges 2 × 2 mm soaked with 0.4 mg/mL 
mitomycin C were applied over the dissected bed, the scleral 
flap and the conjunctiva were draped over the sponges for 
3 minutes, then sponges were removed and the bed was 
  irrigated thoroughly with 50 mL balanced salt solution.
The trabecular block was then removed and a periph-
eral iridectomy was performed, the scleral flap was closed 
with 2 × 10/0 nylon stitches 1 at each side of the flap, the 
  conjunctiva was closed with 2 × 8/0 vicryl sutures, and 
combined antibiotic-steroid drops (tobramycin 0.3% with 
dexamethazone 0.1%) and atropine drops were applied.
Postoperatively, combined antibiotic–steroid drops 
(tobramycin 0.3% with dexamethazone 0.1%) were applied 
6 times a day for 4 weeks and atropine drops were applied 
3 times a day for 2 weeks.
All patients were followed up for 1 week, 1 month, 
3 months, 6 months, and 12 months after injection; cases of 
recurrence of NVI were reinjected with the same dose of IVB 
at the fourth month and then at the eighth month and follow-up 
was completed as regular. Medical treatment was applied to 
control the IOP for nonoperative cases and operative cases 
not controlled after surgery using topical beta blockers then 
combined topical beta blockers and   carbonic anhydrase inhibi-
tors (CAIs). Results were collected, tabulated, and statistically 
analyzed by statistical package SPSS version 19.
Results
The study included 20 eyes of 20 different patients, 8 males 
and 12 females, with a mean age of 58.4 ± 0.99 (range 50 
to 65 years). Mean preoperative VA was 0.1 ± 0.1 and the 
mean IOP was 41.45 ± 5.89 mmHg, and NVI was present 
in all cases. The descriptive statistics of the preinjection and 
follow-up data are shown in Table 1.
Peripheral anterior synechiae were present in 9 cases 
(45%). The causes of retinal ischemia and NVI were prolif-
erative diabetic retinopathy in 13 cases (65%), and central 
retinal vein occlusion in 7 cases (35%).
Two weeks postinjection, all cases showed regression 
of neovessels, 14 cases (70%) showed complete regression, 
6 cases (30%) showed partial regression, and there was no 
change in the angle PAS present in the 9 cases for which 
SST with mitomycin C was performed with a success rate 
of 77.8%. (Criteria for success were IOP # 21 mmHg with 
or without medications, and a functioning bleb.)
Table 1 Descriptive statistics of the preinjection and follow-up 
data
Variable Minimum Maximum Mean Standard   
deviation
Age 50.00 65.00 58.4000 4.4414
VA preinjection 0.05 0.40 0.1135 9.928E-02
iOP preinjection 30.00 50.00 41.4500 5.8891
VA at 12 months 0.05 0.70 0.2310 0.1933
iOP at 6 months 14.00 30.00 19.3000 5.4974
iOP at 12 months 14.00 28.00 17.7000 3.7290
Abbreviations: iOP, intraocular pressure; VA, visual acuity.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Two months postinjection, all cases showed regression 
of NVI, but at 4 months, 5 cases (25%) showed recurrence 
that needed a second injection of IVB (2 cases had previously 
been treated by SST, and 3 cases had not). These 5 cases 
showed clearance of neovessels at 6 months follow-up, and at 
8 months 14 cases (70%) showed recurrence of NVI (6 cases 
had previously been treated by SST, and 8 cases had not), of 
which 9 new cases (45%) needed a second injection and the 
5 previously injected cases (25%) needed a third injection; 
at 12 months all cases showed complete clearance of NVI. 
The recurrence of NVI over the follow-up period is shown 
in Table 2.
Mean IOP at 6 months was 19.3 ± 5.5 mmHg; 15 cases 
(75%) were controlled at IOP # 21 mmHg (6 cases had 
previously been treated by SST, and 9 cases had not), 
2 were controlled with topical beta blockers and 1 with 
combined topical beta blockers and CAIs, and 5 cases 
(25%) were not controlled with combined topical beta 
blockers and CAIs.
At 12 months follow-up, the IOP was controlled in all 
cases with a mean of 17.75 ± 3.74 mmHg (9 cases were 
previously treated by SST, and 11 cases were not); 2 cases 
(10%) were controlled with beta blockers and 2 cases (10%) 
were controlled with combined topical beta blockers and 
CAIs. Three cases had controlled IOP after the third injec-
tion without medication where the combined topical beta 
blocker and CAIs were discontinued. Table 3 shows the 
IOP control and antiglaucoma medications used over the 
follow-up period.
At 12 months follow-up; the mean VA was 0.23 ± 0.19, 
where it improved in 17 cases (85%) from preoperative 
VA of 0.12 ± 0.11 to a postoperative VA of 0.26 ± 0.2. The 
difference in the VA and IOP over the follow-up period is 
shown in Table 4.
Discussion
The treatment of NVG includes PRP, ocular antihypertensive 
medications, glaucoma drainage surgeries, and cyclodestruc-
tive procedures. However, it can be refractory and may not be 
controlled by any of these means.10 Pharmacological treatment 
with IVB may have a good additive effect on IOP control and 
regression of NVI as proved by many studies.11–13
In this case series, 20 eyes of 20 different patients who 
had presented with NVG were injected with IVB 2.5 mg in 
0.1 mL, Peripheral anterior synechiae were present in 9 cases 
(45%) and remained unchanged after injection; subscleral 
trabeculectomy with 0.4 mg/mL mitomycin C for 3 minutes 
was done for these cases.
All cases showed complete regression of NVI within 
2 months after injection, which is consistent with Ileiv 
et al10 who noticed complete regression of NVI at the end 
of follow-up period (range 4 to 16 weeks) in 100% of cases. 
On the contrary, Ghanem et al14 observed complete regres-
sion of NVI in 37.5% of cases within only 2 months and 
Oshima et al15 recorded complete regression in 29% only 
of their cases.
Recurrence of NVI was observed in 4 cases (20%) at 
4 months where reinjection was done, a second recurrence of 
NVI was observed in 14 cases (70%) at 8 months follow-up, 
including the 4 cases that were injected previously, which is 
consistent with the results of Oshima et al15 who reported 
recurrence of NVI in 29% of cases at 2 months after a single 
injection, and those of Ghanem et al14 who reported recur-
rence in 4 cases (25%) at 6 weeks after IVB (although the 
time of recurrence differs between studies), and those of 
Gheith et al16 who reported recurrence in 1 case (17%) after 
3 months and in a second case (17%) after 5 months.
The cause of recurrence seemed to be the persistence of 
retinal ischemia due to inadequate PRP. The recurrence of 
NVI was discovered in the 4 cases that showed the first recur-
rence at 4 months and the second recurrence at 8 months, 
so that PRP was adequately completed in these cases after 
the second recurrence. The recurrence of NVI seemed to be 
Table 2 recurrence of neovascularization over the follow-up 
period
Recurrence 4 months 8 months 12 months
Yes 5 14 0
no 15 6 20
Table 3 intraocular pressure (iOP) control and antiglaucoma 
medications used over the follow-up period
Variable Preinjection 6 months 12 months
iOP 41.45 19.3 17.7
Controlled  
cases
none 15 18
Cases received beta blockers 2 2
Cases received combined beta  
blockers and CAis
1 2
Abbreviations: CAi, carbonic anhydrase inhibitors; iOP, intraocular pressure.
Table 4 The difference in the VA and iOP over the follow-up 
period
Variable t df Sig.
VA preinjection and at 12 months -4.252 19 .000
iOP preinjection and at 6 months 13.650 19 .000
iOP preinjection and 12 months 16.495 19 .000
Abbreviations: iOP, intraocular pressure; VA, visual acuity.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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caused not only by incomplete PRP but also by the limited 
effective period of IVB, so that after a second injection NVI 
regressed again.
Trabeculectomy alone or Ahmed valve operations for 
NVG have a low success rate, probably due to excessive 
intra- and postoperative inflammation and bleeding from 
NVI.17,18
A well functioning bleb was observed after a glaucoma 
filtering procedure combined with IVB.19 IVB was also 
demonstrated to be a valuable addition in the treatment of 
neovascular glaucoma by hastening the resolution of anterior 
segment neovessels, improving the results of glaucoma sur-
geries, and appearing to give long-term control when used in 
combination with PRP in the case series of Gheith et al.16
In our case series, IOP was controlled in 15 cases (75%) 
at 6 months and in 18 cases (90%) at 12 months follow-up. 
After the third injection, the mean IOP dropped from 
41.45 ± 5.89 mmHg preoperatively to 19.3 ± 5.5 mmHg 
at 6 months and 17.75 ± 3.74 mmHg at 12 months post-
operatively, consecutively; the change at 6 and 12 months 
is highly significant with a P value of 0.001 for both. This 
is consistent with the reports of Ileiv et al,10 where mean 
IOP dropped markedly from 36 ± 0.1 mmHg before IVB to 
16.8 ± 3.4 mmHg at the end of the follow-up period (range 
4 to 16 weeks).
There were 5 cases (25%) not controlled at 6 months, 
of which 3 cases were controlled at 12 months after the 
second injection, which proved the role of the third injection 
in IOP control. The success rate of SST with mitomycin C 
after IVB was 77.8%, which is higher than the rate of de 
Moraes et al20 who used SST with mitomycin C with a success 
rate of approximately 58% in 2 years, and consistent with 
the results of Chen et al21 who concluded that IVB might 
be useful adjunctive therapy in addition to trabeculectomy 
in the treatment of NVG. In our case series, however, we 
lacked a control group to compare the effects of SST with 
mitomycin C, with or without IVB. We could have faced 
ethical issues with a control group, because of the well known 
high risk of failure in NVG.
VA was improved in 17 cases (85%) from a preoperative 
VA of 0.12 ± 0.11 to a postoperative VA of 0.26 ± 0.2, due 
to clearance of corneal edema, hyphema, and/or vitreous 
hemorrhage and improvement in macular edema, which was 
not studied in this case series. This improvement in visual 
acuity is highly significant with a P value of 0.001, and was 
higher than that reported by Ghanem et al14 who observed 
improvement in 9 cases (56.25%).
Conclusion
This study showed clearly that IVB had a good additive 
effect in regression of NVI and IOP control in neovascular 
glaucoma cases and also in increasing the success rate of 
SST with mitomycin C. However, IVB has only a limited 
time to work, and repeated injections are needed to maintain 
this effect. More research is needed to clarify the numbers of 
injections needed for different cases of neovascular glaucoma 
and the duration between each injection.
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